Unknown

Dataset Information

0

A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older.


ABSTRACT: For most acute myeloid leukemia (AML) patients an allogeneic hematopoietic stem cell transplantation (HSCT) offers the highest chance of cure. The introduction of less toxic non-myeloablative conditioning (NMA) regimes enabled older and/or comorbid patients to be consolidated with an allogeneic HSCT. While the hematopoietic cell transplantation comorbidity index (HCT-CI) predicted outcomes in many younger patient cohorts its impact in older AML patients receiving NMA-HSCT remains unknown. Here we analyzed 289 AML patients 60 years or older (median age 66, range 60-77 years) undergoing NMA-HSCT (2 or 3 Gray total body irradiation and 3 days of fludarabine 30 mg/m2). HCT-CI risk was low, intermediate, or high in 36%, 31%, and 33% of patients, respectively. Non-relapse mortality (NRM), cumulative incidence of relapse (CIR), and overall survival (OS) did not differ between HCT-CI groups. The HCT-CI also did not impact outcomes when considering the European LeukemiaNet 2017 risk at diagnosis or the measurable residual disease (MRD) status at HSCT. Notably, MRD-negative older NMA-transplanted AML patients had a beneficial OS of 49% after 5 years. Since a higher HCT-CI did not impair outcomes, age or comorbidities per se should not impede NMA-HSCT, presenting a feasible consolidation option for this group of AML patients.

SUBMITTER: Backhaus D 

PROVIDER: S-EPMC9812784 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older.

Backhaus Donata D   Brauer Dominic D   Pointner Rosmarie R   Bischof Lara L   Vucinic Vladan V   Franke Georg-Nikolaus GN   Niederwieser Dietger D   Platzbecker Uwe U   Jentzsch Madlen M   Schwind Sebastian S  

Bone marrow transplantation 20221004 1


For most acute myeloid leukemia (AML) patients an allogeneic hematopoietic stem cell transplantation (HSCT) offers the highest chance of cure. The introduction of less toxic non-myeloablative conditioning (NMA) regimes enabled older and/or comorbid patients to be consolidated with an allogeneic HSCT. While the hematopoietic cell transplantation comorbidity index (HCT-CI) predicted outcomes in many younger patient cohorts its impact in older AML patients receiving NMA-HSCT remains unknown. Here w  ...[more]

Similar Datasets

| S-EPMC9911376 | biostudies-literature
| S-EPMC9911359 | biostudies-literature
| S-EPMC4989381 | biostudies-literature
| S-EPMC4527886 | biostudies-literature
| S-EPMC6234373 | biostudies-literature
| S-EPMC7039394 | biostudies-literature
| S-EPMC3366652 | biostudies-literature
| S-EPMC5791765 | biostudies-literature
| S-EPMC6428294 | biostudies-literature
| S-EPMC11611741 | biostudies-literature